This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Inotiv（NOTV.Q）株式概要
は、米国、オランダ、および国際的な製薬・医療機器業界に非臨床および分析的創薬・開発サービスを提供している。 詳細
NOTV.Q Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
Inotiv, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.011 |
| 52週高値 | US$2.44 |
| 52週安値 | US$0.007 |
| ベータ | 3.92 |
| 1ヶ月の変化 | -23.45% |
| 3ヶ月変化 | -96.32% |
| 1年変化 | -99.47% |
| 3年間の変化 | -99.84% |
| 5年間の変化 | -99.90% |
| IPOからの変化 | -99.87% |
最新ニュース
ナラティブ更新 • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.
ナラティブ更新 • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Recent updates
ナラティブ更新 • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.ナラティブ更新 • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.ナラティブ更新 • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.ナラティブ更新 • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
ナラティブ更新 • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.ナラティブ更新 • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
ナラティブ更新 • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.ナラティブ更新 • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.ナラティブ更新 • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.ナラティブ更新 • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.ナラティブ更新 • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.ナラティブ更新 • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.新しいナラティブ • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.ナラティブ更新 • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).ナラティブ更新 • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.ナラティブ更新 • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).ナラティブ更新 • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).ナラティブ更新 • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.分析記事 • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...分析記事 • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...分析記事 • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
新しいナラティブ • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.分析記事 • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...分析記事 • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...分析記事 • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...分析記事 • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...分析記事 • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...分析記事 • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...株主還元
| NOTV.Q | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | -14.6% | -1.9% | -0.9% |
| 1Y | -99.5% | 25.2% | 14.2% |
業界別リターン: NOTV.Q過去 1 年間で25.2 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: NOTV.Qは、過去 1 年間で14.2 % のリターンを上げたUS市場を下回りました。
価格変動
| NOTV.Q volatility | |
|---|---|
| NOTV.Q Average Weekly Movement | 49.0% |
| Life Sciences Industry Average Movement | 7.2% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: NOTV.Qの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: NOTV.Qの 週次ボラティリティ は、過去 1 年間で29%から49%に増加しました。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1974 | 1,996 | Bob Leasure | www.inotiv.com |
は、米国、オランダ、および国際的な製薬・医療機器業界に非臨床および分析的創薬・開発サービスを提供している。同社は、創薬・安全性評価（DSA）と研究モデル・サービス（RMS）の2つのセグメントで事業を展開している。DMS事業では、製薬会社、大学、政府研究センター、医療研究機関で使用されるライフサイエンス研究用科学機器と関連ソフトウェアを製造し、BASi製品ラインを提供している。RMS事業では、研究用モデル、飼料、寝具、バイオ製品の商業生産と販売を行っている。同社は以前はバイオアナリティカルシステムズ社として知られていたが、2021年3月に社名をイノチブ社に変更した。は1974年に法人化され、インディアナ州ウェストラファイエットに本社を置いている。2026年6月3日、Inotiv, Inc.はその関連会社とともにテキサス州南部地区連邦破産裁判所に連邦破産法第11条に基づく任意整理を申請した。
Inotiv, Inc. 基礎のまとめ
| NOTV.Q 基礎統計学 | |
|---|---|
| 時価総額 | US$387.26k |
| 収益（TTM） | -US$86.97m |
| 売上高(TTM) | US$507.36m |
0.0x
P/Sレシオ0.0x
PER（株価収益率NOTV.Q は割高か？
公正価値と評価分析を参照収益と収入
| NOTV.Q 損益計算書（TTM） | |
|---|---|
| 収益 | US$507.36m |
| 売上原価 | US$390.95m |
| 売上総利益 | US$116.41m |
| その他の費用 | US$203.38m |
| 収益 | -US$86.97m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.49 |
| グロス・マージン | 22.94% |
| 純利益率 | -17.14% |
| 有利子負債／自己資本比率 | 549.2% |
NOTV.Q の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/21 22:48 |
| 終値 | 2026/07/17 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Inotiv, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |